A First-In-Class, Humanized Antibody Targeting Alternatively Spliced Tissue Factor: Preclinical Evaluation in an Orthotopic Model of Pancreatic Ductal Adenocarcinoma

In 2021, pancreatic ductal adenocarcinoma (PDAC) is the 3(rd) leading cause of cancer deaths in the United States. This is largely due to a lack of symptoms and limited treatment options, which extend survival by only a few weeks. There is thus an urgent need to develop new therapies effective again...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, Clayton S., Karve, Aniruddha, Matiash, Kateryna, Stone, Timothy, Li, Jingxing, Wang, Jordon K., Versteeg, Henri H., Aronow, Bruce J., Ahmad, Syed A., Desai, Pankaj B., Bogdanov, Vladimir Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358774/
https://www.ncbi.nlm.nih.gov/pubmed/34395257
http://dx.doi.org/10.3389/fonc.2021.691685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358774/
https://www.ncbi.nlm.nih.gov/pubmed/34395257
http://dx.doi.org/10.3389/fonc.2021.691685

Ejemplares similares